Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

Total article views   HTML views PDF downloads Totals
11,683 Dovepress* 10,286+ 1,694 11,980
PubMed Central* 1,397 490 1,887
Totals 11,683 2,184 13,867
*Since 16 October 2017
Total mentioned Facebook Delicious Reddit Twitter Others
30 1 0 0 14 15

View citations on PubMed Central and Google Scholar